The drug, Lovastatin, and the vitamin, niacin, were compared in a controlled, randomized, open label study of 26 weeks' duration that was conducted at the five lipid clinics. 136 patients with primary hypercholesterolemia participated in the study.
The study consisted of a 4-week diet run-in period after which eligible patients were randomly assigned to receive treatment with either Lovastatin (20 mg/d) or niacin (1.5 g/d) for 10 weeks. On the basis of the LDL cholesterol response and patient tolerance, the doses were sequentially increased to 40 and 80 mg/d of Lovastatin or 3 and 4.5 g/d of niacin after 10 and 18 weeks of treatment.
At 26 weeks, the results showed that niacin and Lovastatin had significantly reduced cholesterol levels (23% and 32% respectively). A key finding, though, was that niacin was more effective than Lovastatin in increasing HDL cholesterol levels -- the "good" cholesterol (33% and 7% respectively).
(Arch Intern Med. 1994 Jul 25;154(14): 1586-95)
